TurboCHO™ High Throughput Platform
From Gene Synthesis to Delivery as Fast as 5 Business Days
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
High throughput (HT) gene to antibody production offers the most cost-effective option for small-scale recombinant antibodies. Empowered by GenScript’s high throughput gene synthesis platform and proprietary TurboCHO™ transient expression technology, small-scale projects, starting from customer-supplied sequences to purified products, can be completed in as short as 5 business days, helping to accelerate therapeutic development and commercialization globally!
Key features:
1. As fast as 5 business days
2. A large capacity of 1,000+ targets/day
3. Multiple isotypes, IgGs, Fab, scFv, VHH, bi-specific antibodies, and more
4. Flexible quantities (i.e., from ug to mg)
Relevant applications:
High throughput screening at the early stage of antibody drug discovery
Enhance productivity and purity in next-generation bispecific antibody manufacturing
Monday, July 14, at 15:00 BST | 16:00 CEST | 10:00 EDT | 7:00 PDT
Bispecific antibodies (BsAbs) are at the forefront of next-generation antibody therapies, offering immense potential but also presenting significant production challenges, such as secretion inefficiencies, chain mispairing, and impurity formation.
Join Dr. Heng Tai Liew, Senior Protein Scientist at GenScript Biotech and discover how GenScript's TurboCHO™ technology overcomes these hurdles through an integrated and iterative workflow that optimizes cell lines, vectors, and media using Design of Experiments (DOE) to refine chain ratios and boost yields. This approach is complemented by a both streamlined and customized purification strategy that utilizes advanced chromatography techniques, enabling selective impurity removal based on molecular differences to achieve superior purity.
Real-world case studies validate the efficacy of this systematic method, demonstrating its capacity to resolve common BsAb production obstacles and support a range of formats from early-stage development through to clinical-scale manufacturing.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
From Sequence to AI-Ready Data: Accelerating AI Drug Discovery with 4-Day Validation
Thursday, September 3 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
AI-driven drug discovery (AIDD) is transforming antibody discovery and biologics development, enabling researchers to generate larger candidate pools and explore increasingly complex therapeutic antibody formats. But as AI accelerates innovation, biological validation has emerged as a critical bottleneck in the Design-Build-Test-Learn (DBTL) workflow. The challenge is no longer identifying promising candidates, it is validating them quickly enough to keep pace.
Join SelectScience® and Dr. Siyuan Zhao to discover practical strategies for accelerating antibody research and biologics development using GenScript's TurboCHO™ 3.0 expression platform and AI-driven drug discovery technologies. Drawing on experience across both academia and the biopharmaceutical industry, Dr. Zhao will share insights into overcoming biological validation challenges, generating high-quality AI-ready datasets, and making faster, more confident data-driven decisions.
You will learn how high-throughput protein expression, workflow automation, multi-platform validation, and AI-ready data generation can streamline antibody screening, support complex biologic modalities, and accelerate the development of next-generation therapeutic antibodies.
Whether you are looking to increase screening efficiency, shorten development timelines, or maximize the value of AI in your workflow, this webinar will provide actionable insights to help you move from sequence to data faster.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
